Hello, my name is Tim Elliott.
I'm the Kidani Professor of Immuno-oncology.
I work at the University of Oxford in the UK.
In this lecture, I'm going to give a brief introduction
to the basic principles of cancer immunotherapy.
I recommend you listen to an accompanying lecture in the same series here
on cancer immunology and this would serve as
a good primer to the lecture you're about to see now.
This cartoon describes in very basic terms,
the relationship between our immune system and a growing tumor.
We know that it's possible to prime T-cells to tumor antigens.
Those T-cells, when they become activated,
can home into the site of tumor development in a tissue where they
join other tissue-resident lymphocytes and together, these can kill tumor cells.
And that this process of tumor ablation can balance any cell division that's
occurring in tumor cells and a period of so-called tumor equilibrium can ensue.
We also know, however,
that tumors can escape this immune attack either by
inducing functional exhaustion in T-cells or by inducing
any immunosuppressive tumor microenvironment by attracting suppressive cells to
the microenvironment or by
reprogramming tissue-resident cells to become immunosuppressive.
Well, the tumors can simply lose the ability to
present and process antigens to those T-cell.
They escape simply because they become invisible and this then leads
to a period of tumor progression which is clinically potentially lethal.
Now, each one of these stages is a potential target for immunotherapy.
I'll go through these in turn throughout my lecture.